BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12901346)

  • 1. Pathogenic markers in essential thrombocythemia.
    Gale RE
    Curr Hematol Rep; 2003 May; 2(3):242-7. PubMed ID: 12901346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia.
    Vannucchi AM; Grossi A; Pancrazzi A; Antonioli E; Guglielmelli P; Balestri F; Biscardi M; Bulgarelli S; Longo G; Graziano C; Gugliotta L; Bosi A
    Br J Haematol; 2004 Oct; 127(2):214-9. PubMed ID: 15461629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia.
    Puigdecanet E; Espinet B; Villa O; Florensa L; Besses C; Serrano S; Solé F
    Cancer Genet Cytogenet; 2006 May; 167(1):39-42. PubMed ID: 16682284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.
    Dillon M; Minear J; Johnson J; Lannutti BJ
    Leuk Res; 2008 May; 32(5):811-9. PubMed ID: 17980909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of prv-1 and c-mpl markers in polycythemia vera and essential thrombocythemia.
    Pahl HL
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):202, 204. PubMed ID: 16163180
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
    Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
    Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
    Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
    Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
    Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytosis and thrombocythemia.
    Schafer AI
    Blood Rev; 2001 Dec; 15(4):159-66. PubMed ID: 11792116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.
    Tefferi A; Murphy S
    Blood Rev; 2001 Sep; 15(3):121-31. PubMed ID: 11735160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.
    Teofili L; Martini M; Luongo M; Di Mario A; Leone G; De Stefano V; Larocca LM
    J Clin Oncol; 2002 Oct; 20(20):4249-54. PubMed ID: 12377969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
    Kralovics R; Skoda RC
    Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating thrombopoietin in clonal versus reactive thrombocytosis.
    Karakuş S; Ozcebe OI; Haznedaroğlu IC; Göker H; Ozatli D; Koşar A; BüyükaşIk Y; Ertuğrul D; SayInalp N; KirazlI S; Dündar SV
    Hematology; 2002 Feb; 7(1):9-12. PubMed ID: 12171772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic control of PRV-1 expression on neutrophils.
    Jelinek J; Li J; Mnjoyan Z; Issa JP; Prchal JT; Afshar-Kharghan V
    Exp Hematol; 2007 Nov; 35(11):1677-83. PubMed ID: 17976520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
    Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
    Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
    Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
    Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.